导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.33% | 2900/4773 |
| 近一周 | -2.17% | 1379/5462 |
| 近一月 | -4.13% | 2243/5421 |
| 近一季 | -7.21% | 2332/5209 |
| 近半年 | -2.54% | 1945/4920 |
| 近一年 | 0.27% | 2604/4366 |
| 近两年 | 42.59% | 1757/2954 |
| 近三年 | 25.87% | 1241/2253 |
| 成立以来 | 22.35% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.26% 3578/4961 |
12.07% 2240/5312 |
- - |
- - |
| 2025 | 19.96% 2162/4813 |
-0.87% 2441/3635 |
2.33% 1645/4076 |
17.90% 2404/4524 |
0.31% 2067/4813 |
| 2024 | 15.43% 929/3463 |
2.92% 667/2808 |
-0.94% 876/3014 |
14.94% 1869/3129 |
-1.51% 1734/3463 |
| 2023 | -8.92% 1072/2656 |
4.32% 984/2280 |
-3.84% 924/2385 |
-2.92% 790/2515 |
-6.47% 1792/2655 |
| 2022 | -21.75% 1047/2207 |
-13.93% 876/1919 |
6.82% 600/2016 |
-13.74% 964/2113 |
-1.33% 1693/2208 |
| 2021 | -3.62% 918/1822 |
-2.98% 736/1255 |
3.97% 941/1330 |
-5.91% 877/1466 |
1.54% 886/1822 |
| 2020 | 22.73% 665/1250 |
-11.31% 836/1028 |
12.70% 675/1067 |
10.54% 537/1164 |
11.08% 566/1184 |
| 2019 | - - |
- - |
- - |
- - |
6.42% 612/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 工银沪深300ETF联接C VS. 长安沪深300非周期A(740101) |